Will ICON’s Anthropic collaboration reduce clinical trial delays and protocol amendments?
ICON and Anthropic will build Claude-powered clinical trial tools inside Orbis, targeting site selection, enrolment risk and protocol design.
Features & Analysis
Pharma & Biotech
What Rohan Palekar’s appointment means for Newleos and its anxiety drug pipeline
Newleos names Rohan Palekar board chairman as three neuropsychiatry programs move through clinical proof-of-concept. Read the analysis.
Medical Devices & Diagnostics
Can Seegene’s million-case GMCS establish a new standard for HPV and STI testing?
Seegene will test whether combined HPV and STI PCR panels can improve reproductive infection care through its million-case GMCS.
Pharma & Biotech
CSL plans expanded pediatric ANDEMBRY filing after positive garadacimab Phase 3b data
CSL’s pediatric ANDEMBRY data support filings in children aged 2 to 11, but regulators still need full safety, PK and efficacy results.
Medical Devices & Diagnostics
Why American Industrial Partners paid $1.27bn for Avanos Medical
American Industrial Partners completes its $1.27 billion Avanos Medical acquisition, taking the medtech company private to accelerate growth and execution.
Pharma & Biotech
How BioMarin and n-Lorem plan to develop an antisense therapy for ReNU syndrome
BioMarin and n-Lorem launch a preclinical antisense program targeting the RNU4-2 variant behind most ReNU syndrome cases.
Pharma & Biotech
Can one injection replace two? DifGen’s DFGN-101 enters clinical development through a streamlined FDA pathway
DifGen’s DFGN-101 can enter clinical testing after FDA IND clearance, advancing a single-injection approach for advanced breast cancer.
Medical Devices & Diagnostics
How could CyPath Lung fit into pulmonary nodule evaluation after low-dose CT screening?
bioAffinity’s CyPath Lung framework targets pulmonary nodule decisions, but adoption still depends on prospective validation and payer support.
Pharma & Biotech
Cognizin citicoline enters neuromuscular research as Kirin reports early cell-model findings
Kirin’s Cognizin citicoline improved neuromuscular junction markers in cell models, opening a new research path that still needs human trials.
Pharma & Biotech
What will Insilico Medicine reveal about ISM6331 at the ESMO 2026 Congress?
Insilico Medicine’s first human data for ISM6331 will arrive as clinical interest in TEAD inhibition is accelerating. The presentation must show whether the AI-designed molecule can combine credible antitumor activity with a dose and safety profile suitable for further development.